优先考虑用于阿尔茨海默病的可重复使用药物,使用基于网络的分析,同时评估长QT综合征风险
Alessio Funari1,2, Enrico De Smaele3, Paola Paci2,4
1Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Biotechnology reports (Amsterdam, Netherlands)
|August 12, 2025
概括
这项研究提出了一种新的网络方法,用于识别阿尔茨海默病的安全药物重新定位候选者,最大限度地降低心脏副作用风险. 确定了有前途的化合物,有可能逆转与疾病相关的基因表达.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 计算生物学 计算生物学
背景情况:
- 阿尔茨海默病 (AD) 影响数百万,有效治疗方法有限,没有治愈.
- 药物重新定位为AD治疗提供了一种策略,但会带来意外副作用的风险.
- 延长QT间隔是AD患者使用某些药物的令人担忧的心脏副作用.
研究的目的:
- 开发一种基于网络的方法,用于识别阿尔茨海默病的安全药物重定向候选人.
- 为了最大限度地降低QT间隔延长的风险,一个已知的心脏副作用,在AD的药物重新定位期间.
- 为了确定具有潜力减轻AD病理和逆转疾病相关基因表达的特定化合物.
主要方法:
- 综合作用模式和随机步行与重新启动分析用于药物候选物识别.
- 基于网络的方法来评估和最小化药物重新定位中的QT间隔延长风险.
- 基因组丰富分析,以评估已识别的化合物逆转AD相关基因表达特征的潜力.
主要成果:
- 确定了阿坎普罗沙特,托尔卡,西塔格利普丁和氧化物作为阿尔茨海默病的有希望的药物重新定位候选人.
- 基于网络的方法成功地整合了药物作用和QT延长的风险评估.
- 计算分析表明,这些化合物可能会逆转与阿尔茨海默病相关的关键基因表达模式.
结论:
- 一个基于网络的新策略有效地通过药物重新定位来识别潜在的阿尔茨海默病治疗方法,同时减轻心脏风险.
- 阿卡姆普罗沙特,托尔卡,西塔格利普丁和氧化物是阿尔茨海默病治疗中进一步研究的有希望的候选人.
- 这种方法提升了药物重定向的安全性和有效性,用于像阿尔茨海默病这样的复杂神经系统疾病.
相关概念视频
Alzheimer's Disease: Treatment
261
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
261
Alzheimer's Disease: Overview
668
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
668
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
206
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
206


